Biocept Stock News

Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering 1,176,470 shares of its common stock and warrants

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an unde

Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company's common stock will begin trading on a split-adjusted basis as of

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that

Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay system off the ground in 2023. Interim CEO Samuel

Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed that the first patient with leptomeningeal metastases has been enrolled in the FORESEE clinical tr

Biocept, Inc. (NASDAQ:BIOC ) Q3 2022 Earnings Conference Call November 28, 2022 4:00 PM ET Company Participants Jody Cain - LHA Investor Relations Sam Riccitelli - Chairman and Interim President and C

Biocept Inc (NASDAQ:BIOC) has reported a 176% year-over-year jump in orders for its CNSide product, a cerebrospinal fluid assay addressing unmet needs for patients with central nervous system metasta

Biocept Inc (NASDAQ:BIOC) said it has appointed certified public accountant Quyen Dao-Haddock to its board of directors, bringing her more than 20 years of financial and accounting experience to the

Biocept Inc (NASDAQ:BIOC) said it is participating in a study evaluating biomarkers associated with central nervous system (CNS) metastasis in patients with metastatic breast cancer and brain metastas

Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -28.57% and 17.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st

Biocept Inc (NASDAQ:BIOC) told investors it was continuing to position itself as a "leader in neurological tumor diagnostics" as the company released second-quarter results, which included the first r

Agiliti (AGTI) delivered earnings and revenue surprises of 5.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biocept Inc (NASDAQ:BIOC) revealed that it has expanded the commercial availability of CNSide, which is based on its proprietary quantitative tumor cell capture and detection method, paired with assay